GNPX Stock News & Analysis | Latest Updates

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

(NASDAQ:GNPX) Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, Sept. 2, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with...

September 2, 2025Investor

GNPX News

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Lincoln Park To Purchase Up To $12.5M In Genprex Shares

Genprex Announced That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of GPX-002, Diabetes Gene Therapy Drug Candidate, In An Oral Presentation At The American Society Of Gene And Cell Therapy's 28Th Annual Meetin

Genprex Files For Offering Of 27,586,206 Shares Together With Warrants At $0.29 Per Share And Warrant

Genprex Q1 EPS $(0.26) Beats $(0.41) Estimate

Genprex Enters Sponsored Research Agreement With The University Of Pittsburgh To Study Diabetes Gene Therapy In Type 1 And Type 2 Diabetes

Genprex Announced It Has Entered Into An Exclusive Patent License Agreement With Uthealth Houston Granting Genprex Exclusivity And Commercial Rights Relating To Its Lead Drug Candidate, Reqorsa Gene Therapy (Quaratusugene Ozeplasmid) For The Potential Tre

Genprex Enters Exclusive Patent License To Additional Gene Therapy Technology With UTHealth Houston For The Treatment Of Glioblastoma

Genprex's Gene Therapy Shows Results for Lung Cancer Treatment at AACR Meeting

Genprex Collaborators To Present Preclinical Data And Research From Studies Of GPX-002, Diabetes Gene Therapy, At ASGCT 28Th Annual Meeting

Genprex Signs Exclusive Patent License Agreement With NYU Langone Health Related To Drug Candidate, Reqorsa Gene Therapy

Genprex Selected To Present Trial Design Of Acclaim-3 Clinical Trial Evaluating Reqorsa Gene Therapy In Small Cell Lung Cancer At 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published In Cancer Research Supplement Proceedings On The Use Of Reqorsa Gene Therapy For The Treatment Of Lung Cancer

Genprex Research Collaborators To Present At AACR 2025

enprex Announces Strategic CDMO Collaboration For Diabetes Gene Therapy Using Non-Viral Delivery System

Genprex Announces Amended License Agreement With University Of Pittsburgh For Gene Therapy Technologies In Diabetes; Forms Subsidiary Convergen Biotech For Diabetes Program Development

Genprex Says Its Research Collaborators Published Study Titled 'NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.' In eLife

Genprex Secures Exclusive License From University Of Michigan For Reqorsa Gene Therapy In Combination With ALK-Inhibitors To Target ALK-Positive Lung Cancer

Genprex Collaborators Present Preclinical Data On Reqorsa Gene Therapy At The Society For Immunotherapy Of Cancer 2024 Annual Meeting; REQORSA Modulates In Vivo Immune Responses Against Cancers

HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target